Jin Rong Jie·2025-08-12 02:13Core Viewpoint - Fosun Pharma's stock price increased by 7.55% to HKD 20.8 following the announcement of a licensing agreement with Expedition Therapeutics for the development of a DPP-1 inhibitor [1] Group 1: Licensing Agreement Details - Fosun Pharma's subsidiary, Shanghai Fosun Pharmaceutical Industry Development Co., Ltd., signed a licensing agreement with Expedition Therapeutics for the global development, production, and commercialization rights of the DPP-1 inhibitor XH-S004, excluding mainland China and Hong Kong/Macau [1] - Fosun Pharma retains the development, production, and commercialization rights of XH-S004 within mainland China and Hong Kong/Macau [1] Group 2: Financial Terms of the Agreement - Expedition will pay up to USD 120 million in non-refundable upfront payments and milestone payments for development [1] - Additionally, Expedition may pay up to USD 525 million in sales milestone payments based on the annual net sales performance of XH-S004 in the licensed regions [1] Group 3: Clinical Trial Status - XH-S004 is currently in Phase II clinical trials for the treatment of non-cystic fibrosis bronchiectasis in mainland China and in Phase Ib clinical trials for chronic obstructive pulmonary disease (COPD) [1]